首页|卵巢癌铂类化疗耐药的分子机制研究进展

卵巢癌铂类化疗耐药的分子机制研究进展

扫码查看
铂类药物是卵巢癌最有效的化疗药物之一,虽然铂类化疗的初始反应高达80%,但耐药性很常见。在大多数晚期患者中,最终复发和死亡是由获得性耐药所引起。卵巢癌化疗耐药性是影响其治疗效果的重大障碍,然而化疗耐药其病因不清、机制复杂,是临床及科研中急需解决的难点和热点。因此,卵巢癌耐药机制的研究将为卵巢癌化疗的探索及研发提供依据。现关于卵巢癌铂类耐药的分子机制进行综述。
Advances in molecular mechanisms of resistance to platinum chemotherapy in ovarian cancer
Platinum drugs are one of the most effective chemotherapy drugs for ovarian cancer,and although the initial response to platinum chemotherapy is as high as 80%,resistance is common.In most advanced patients,eventual relapse and death are caused by acquired resistance.Chemotherapy resistance of ovarian cancer is a major obstacle affecting its therapeutic effect.However,the cause of chemotherapy resistance is unclear and the mechanism is complex,which is a difficult and hot point in clinical and scientific research.Therefore,the study of drug resistance mechanism of ovarian cancer will provide a basis for the exploration and development of chem-otherapy for ovarian cancer.This article reviews the molecular mechanism of platinum resistance in ovarian cancer.

ovarian cancerplatinum chemotherapy resistancemolecular mechanism

刘影、梁义娟、解丹、闫丽伟、刘璐、王伟明

展开 >

河北大学附属医院妇科, 河北 保定 071000

河北大学临床医学院, 河北 保定 071000

卵巢癌 铂类化疗耐药性 分子机制

河北省政府项目河北大学医学学科培育项目

ZF20242182020B06

2024

医学研究与教育
河北大学

医学研究与教育

影响因子:0.675
ISSN:1674-490X
年,卷(期):2024.41(1)
  • 59